seven patients with refractory stage iii ovarian carcinoma were treated with escalating doses of human recombinant interleukin 2 ( ril-2 ) administered via the intraperitoneal ( ip ) route in an attempt to establish a dose and schedule of ril-2 suitable for prolonged outpatient ip administration .
C0218986
human recombinant interleukin 2
C0021756
ril-2